Benitec Biopharma Q1 2026: $100mln raised, BB-301 OMPD registrational program funded.
ByAinvest
Friday, Nov 14, 2025 5:35 pm ET1min read
BNTC--
• Benitec Biopharma releases Q1 2026 financial results and operational update. • BB-301 granted Fast Track Designation by FDA. • Positive interim clinical study results for BB-301 show 100% responder rate. • First patient in Cohort 2 successfully treated with BB-301 in Q4 2025. • Company raises $100 million in oversubscribed public offering of common stock. • Funds expected to support advancement of BB-301 OMPD registrational program and regulatory filing activities.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet